Kornimate/medical-research-clean huggingface dataset:
protocol memory deficit in patients with obstructive sleep apnea syndrome

Conditions: Memory Deficit

Summary: the main objective of this study is to evaluate the evolution of memory deficit (verbal episodic memory, procedural memory, working memory, short-term memory) in sleep apnea obstructive syndrome (saos) patients after treatment by continuous positive airway pressure treatment (cpap). for thus, we will compare memory tests in two separate groups of saos patients with "effective " versus "ineffective" ( or sham) cpap, before and 6 weeks after the beginning of the treatment. thus we will assess the evolution of memory deficit, the effectiveness of the treatment on the evolution of memory deficit before and 6 weeks after the beginning of the treatment by "effective " versus "ineffective" cpap. we feel the results of the tests of memory will show greater memory disorders in patients with saos before beginning the treatment rather than six weeks afterwards. thus we hypothesise that, after the treatment by "effective" cpap, the patients with saos will have greater improvement of their memory disorders than those treated by "sham cpap".

we want to assess the evolution, before and 6 weeks after the beginning of the treatment, of the significant differences of the performances of the various memory tests evaluating several forms of memory (episodic memory, working memory, short-term memory and procedural memory) according to the treatment for patients with saos (effective versus sham).

Eligibility criteria:
inclusion criteria: * major patients, * agreeing, * diagnosed suffering from the saos, * regulation by the specialist in a treatment by cpap, * patients do not begin the treatment * affiliated to the social security, * fluent in french. exclusion criteria: * patients presenting severe depressive disorders (hads score\>19), * intellectual deterioration (mms\< 28), * a functional failure of the dominant arm upper limb inhibiting realization of graphic tasks, * an associated oxygen treatment, * suffering from cancer, * cerebro-vascular accident, * pregnant or nursing women, * adult under supervision or trusteeship, * patients already included in another research protocol or in period of exclusion, * antidepressant and anxiolytic treatment.

Keywords: sleep apnea obstructive syndrome (saos) memory deficit continuous positive airway pression (cpap) sham cpap
phase ii trial of individualized immunotherapy in early-stage unfavorable classical hodgkin lymphoma

Conditions: Classical Hodgkin Lymphoma

Summary: the aim of the trial is to establish an individualized first-line treatment incorporating checkpoint inhibition for early-stage unfavorable chl, which is effective and well tolerated.

programmed cell death protein-1 (pd-1) blockade is highly effective and well tolerated in relapsed or refractory chl and has also demonstrated efficacy in the first-line treatment of chl in combination with doxorubicin, vinblastine, and dacarbazine (avd) in the phase ii ghsg nivahl trial. a relevant proportion of patients achieved an early metabolic complete remission (cr) with anti-pd-1 monotherapy and might not require standard chemo- or radiotherapy. limiting therapy-associated short- and long-term side effects of these conventional treatments including impaired quality of life, second primary malignancies or organ damage is of utmost importance in the predominantly young chl patients. this trial will hence further reduce treatment intensity and provide a chemo- and radiotherapy-free therapy to optimally responding patients.

Eligibility criteria:
inclusion criteria: * age 18-60 for the main trial cohort * age ≥ 61 years and eligible for avd as determined by cirs-g score and investigator for the exploratory cohort * first diagnosis of treatment-naïve chl * early-stage unfavorable disease (i.e. stage ia, ib and iia with risk factors a-d, stage iib with risk factors c-d): 1. large mediastinal mass 2. extranodal lesion(s) 3. elevated erythrocyte sedimentation rate 4. ≥ 3 nodal areas exclusion criteria: * presence of nodular-lymphocyte predominant hodgkin lymphoma, grey-zone lymphoma and/or central nervous system involvement of lymphoma
does the amh concentration depend on the menstrual cycle?

Conditions: Reproductive Sterility

Summary: during two none subsequent natural menstrual cycles healthy female participants will be subjected every second day to blood sampling and 3d-ultrasound examinations. together with four other key hormones the concentration of amh (anti-muellerian hormone) will be measured in the serum.

during two none subsequent natural menstrual cycles healthy female participants will be subjected every second day to blood sampling and 3d-ultrasound examinations. together with four other key hormones the concentration of amh will be measured in the serum. half of the serum samples will immediately be subjected to hormone analysis whereas the other half will be stored frozen at -80 °c. after conclusion of the study the frozen samples will be subjected to re-measurment again a reference laboratory. the aim is to study the stability of the amh elecsys assay under both conditions. the participants will be health women aged between 18 and 40 years. they will be grouped into a younger and an older group. they will be observed during one menstrual cycle, then they will remain unobserved during a second menstrual cycle, and then again they will be observed during a third menstrual cycle.

Eligibility criteria:
inclusion criteria: * regular menstrual cycles, between 24 and 32 d. * body mass index between 24 and 32 kg/m2 * no hiv, no hepatitis b and c * no smoking exclusion criteria: * intake of reproductive hormones, including birth control pill * pregnancy or breastfeeding * infertility * polycystic ovary syndrome

Keywords: natural menstrual cycle amh 3d ultrasound
effectiveness of electrical stimulation or kinesio taping on recovery disability in low back pain

Conditions: Chronic Low Back Pain

Summary: the purpose of this study is to analyze the effectiveness of electrical stimulation and kinesio taping in combination with exercise in people with chronic low back pain


Eligibility criteria:
inclusion criteria: 1. lbp for three months or more; 2. age between 25 and 65 years; 3. a score of four points or more on the roland morris disability questionnaire; 4. not currently receiving physical therapy. exclusion criteria: 1. the presence of lumbar stenosis; 2. any clinical signs of radiculopathy; 3. a diagnosis of spondylolisthesis; 4. a diagnosis of fibromyalgia; 5. treatment with corticosteroid or oral medication within the past two weeks; 6. a history of spinal surgery; 7. disease of the central or peripheral nervous system.

Keywords: electrical stimulation therapy kinesio taping exercise
effect of dexmedetomidine combined with sufentanil for postoperative intravenous analgesia in neurosurgery

Conditions: Arteriovenous Malformation

Summary: the purpose of this study is to determine effect of combined medication of sufentanil and dexmedetomidine in patient controlled analgesia after neurosurgery.

sufentanil is a classical drug for postoperative analgesia. dexmedetomidine is a commonly used α2-adrenergic receptor, and it helps provide sedation, analgesia and inhibition of sympathetic activation. the investigators propose to recruit 120 patients who is undergoing the arteriovenous malformation embolism operation in department of neurosurgery. patients will be randomly divided into 4 groups(control group, sufentanil and low dexmedetomidine dose group, sufentanil and middle dexmedetomidine dose group, sufentanil and high dexmedetomidine dose group), then the investigators select post-operative records to determine whether dexmedetomidine can take a positive role in neurosurgical analgesia.

Eligibility criteria:
inclusion criteria: 1. patients undergoing venous malformation embolization operation through general anesthesia. 2. aged 18-65 years old. 3. operating time varies 1-4h,and extubation after the operation. exclusion criteria: 1. long-term use of analgesics,sedatives or non steroidal anti-inflammatory drugs history. 2. known for dexmedetomidine or other drugs allergy in this study. 3. cannot communicate. 4. preoperative systolic blood pressure \<90 mmhg, or the heart rate \<50/min.

Keywords: dexmedetomidine patient controlled analgesia
prospective monitoring of bnt162b2 second vaccination booster effects in health care workers (hcw)

Conditions: Coronavirus Infections

Summary: the sars-cov-2 virus causes severe respiratory illness and is an ongoing global pandemic. on december 12, 2020 the fda approved pfizer's biontech vaccine bnt162b2 which is a messenger rna type of vaccine for use. this vaccine has shown in numerous studies the ability to induce a strong immune response and provide both humeral and cellular protection against wild type, alpha and delta variants of sars-cov2 virus. in israel the national vaccine operation began in mid-december 2020 which included 2 initial doses three weeks apart. in august 2021 a first booster (3rd dose) was provided to enhance protection and due to reports of reduced immune response and clinical protection. several studies have demonstrated that over time there is a decay in the antibody levels, and with them reduced protection. recently a new variant of concern has been identified (omicron) and is causing a surge of infections worldwide. there is lack of knowledge regarding the effectiveness of the current schedule of vaccine against this new variant and whether a second booster (4th dose) will provide higher levels of clinical protection against this variant, currently the ministry of health is considering recommendations for a fourth dose for hcw. the purpose of this study is to examine whether a fourth dose of vaccination will provide better protection against infection and clinical disease.


Eligibility criteria:
inclusion criteria: 1. able to provide written informed consent. 2. healthcare worker in one of the clalit health services medical centers and is at least 18 years of age. 3. completed three doses of bnt162b2 according to moh guidelines. 4. third dose was given at least 4 months prior to enrollment. exclusion criteria: 1. history of covid-19 infection. 2. history of being treated or is currently being treated for any type of malignancies or other co-morbid conditions that may result in protocol non-compliance. 3. currently or in the past three months was treated with any type of immune suppression medication (including chemotherapy, immunomodulatory drugs, biological agents that affect the immune system, any immunosuppressive drug such as corticosteroids). 4. received in the past 4 months monoclonal antibodies of any type.
evaluate the performance of journey ii cr and journey ii bcs in tka populations

Conditions: Arthroplasty; Replacement; Knee

Summary: background: the journey ii bcs total knee system (journey ii bi-cruciate stabilized total knee system) consists of femoral component made from oxidized zirconium (oxinium) the journey ii cr total knee system (journey ii cruciate retaining total knee system ) consists of femoral component made from oxidized zirconium (oxinium) purpose: post-market evidence generation for journey ii bcs and journey ii cr total knee system objectives: 1. evaluate the performance of journey ii tka in asia-pacific (apac) patient populations 2. establish the equivalent performance between journey ii bcs and journey ii cr to support adoption of journey ii cr research participants / locations: a total of at least 176 knees' information will be collected in up to 10 sites. there will be at least eighty-eight (88) knees for journey ii cr tka group and at least 88 knees for journey ii bcs tka group.


Eligibility criteria:
inclusion criteria: * subjects with degenerative osteoarthritis. * subject is planning to have bilateral total knee arthroplasty (tka) using journey ii bcs \& cr or have unilateral tka using journey ii bcs or journey ii cr.\* * subject is able and willing to provide voluntary consent to study participation. * subject is 18-80 years old (inclusive). \[\* bilateral cases can be simultaneous bilateral or staged bilateral (which an interval of 6-8 weeks apart between both knees)\] exclusion criteria: * subjects with rheumatoid arthritis/inflammatory arthritis, posttraumatic arthritis. * previous surgeries including high tibial osteotomy (hto), unicondylar knee arthroplasty (uka) or total knee arthroplasty (tka) on the subject knee. * subject is pregnant or breast feeding or those at a child-bearing age planning to become pregnant during the follow up. * subject does not meet the indication or is contraindicated for journey ii bcs \& journey ii cr's instructions for use (ifu).

Keywords: osteoarthritis total knee arthroplasty (tka) cruciate retaining (cr) bi-cruciate stabilized (bcs)
immunopathogenesis of chlamydia

Conditions: CHLAMYDIA INFECTIONS

Summary: sexually transmitted chlamydia trachomatis infections are a widespread public health concern due to their prevalence and potentially devastating reproductive consequences, including pelvic inflammatory disease, infertility, and ectopic pregnancy. the goal of this study is to evaluate the risk factors for adverse outcomes following genital tract infection with chlamydia trachomatis and to evaluate whether or not the presence of c. trachomatis in the rectum act as a reservoir for infection.

sexually transmitted chlamydia trachomatis infections are a widespread public health concern due to their prevalence and potentially devastating reproductive consequences, including pelvic inflammatory disease, infertility, and ectopic pregnancy. the goal of this study is to evaluate the risk factors for adverse outcomes following genital tract infection with chlamydia trachomatis and to evaluate whether or not the presence of c. trachomatis in the rectum act as a reservoir for infection. our target population will be adolescent females age 11-21 evaluated at the ach adolescent center who are undergoing pelvic examinations or urine screening for sexually transmitted infections (stis). laboratory specimens obtained will include cervical and rectal swabs, urine and blood specimens, as well as, chart review and comprehensive subject interviews in the initial data collection with follow-up evaluations at 3, 6, 12, 24 and 36 months for qualifying subjects

Eligibility criteria:
inclusion criteria: * female * 11 to 21 years of age at the time of enrollment * positive for chlamydia infections by urine or cervical pcr * 5th chlamydia-negative subject who fits all other inclusion criteria * negative pregnancy test * written informed consent provided * signed a hipaa authorization form * willingness to comply with all the requirements of the protocol exclusion criteria: * positive pregnancy test * negative for chlamydia, unless 5th negative subject to be in the control group * any condition that in the opinion of the investigator would interfere with the ability of the potential subject to complete the study or would result in significant risk to the subject

Keywords: chlamydia chlamydia trachomatis adolescent health female health sexually transmitted infections infertility pelvic inflammatory disease
the drug-drug interaction of shr4640 and febuxostat in patients with hyperuricemia

Conditions: Hyperuricemia

Summary: the objective of the study is to assess the pharmacodynamic properties of drug-drug of shr4640 and febuxostat interaction in patients with hyperuricemia.


Eligibility criteria:
inclusion criteria: 1. subject has a body mass index ≥18 and ≤30 kg/m2; 2. screening sua value ≥8mg/dl; 3. subject has no clinically relevant abnormalities in vital signs, ecg, physical examination，imaging examination or safety laboratory values. exclusion criteria: 1. subject known or suspected of being sensitive to the study drugs or its ingredient； 2. alt、ast、tbil\>uln; 3. history of kidney stones or screening kidney stones by b-ultrasound； 4. history of malignancy； 5. history of xanthinuria； 6. donated blood（≥400ml）within 3 months prior to screening or received transfusion of blood。
hyperproteic nutrition:correlation of bun to nitrogen balance

Conditions: Enteral Feeding

Summary: this study is designed to determine if the following are true. when protein requirements exceed metabolic requirements, blood urea nitrogen(bun) levels will rise. elevated bun levels in the absence of renal failure, hepatic failure, or gi bleeding, will be correlated with improved nitrogen balance and inversely correlated with infection rates, days of mechanical ventilation, icu days, and total hospital days.

the purpose of this study is threefold. first, to determine if a correlation exists between bun and nitrogen balance in the context of hyperproteic nutrition administration. creatinine clearance will also be followed to determine if there is any harmful effect to the kidney secondary to an elevated bun. secondly, to determine if there is a difference in hospital acquired infection rate, ventilator days, icu days, and hospital stay between the current nutrition standard at penn state hershey medical center and a hyperproteic nutrition protocol. thirdly, to determine the accuracy of at least three calculated creatinine clearance formulae when compared to a measured creatinine clearance.

Eligibility criteria:
inclusion criteria: * greater then or equal to 18 years of age and patient in intensive care unit * receiving enteral nutrition, with expected duration of at least 5 days * blood urea nitrogen and creatinine clearance are part of routine blood work * indwelling urinary catheter in place exclusion criteria: * renal or hepatic failure * current or history(past 6 mos) of gi bleeding * serum creatinine on day of screening of equal to or greater then 1.5 mg/dl * creatinine clearance on day of screening of equal to or less then 30ml/min * hypovolemia resulting in increased bun * septic shock * blood urea nitrogen on day of screening equal to or greater then 30mg/dl

Keywords: blood urea nitrogen nitrogen balance nutrition intensive care
national comprehensive cancer network (nccn) decision support tool for patients with nsclc

Conditions: Non-small Cell Lung Cancer

Summary: this study involves the evaluation of a decision support tool, based on the patient version of the nccn guidelines, for the non-small cell lung cancer patient population.

this study involves the evaluation of a decision support tool, based on the patient version of the nccn guidelines, for the non-small cell lung cancer patient population. the decision support tool is offered by a trained coordinator to the patient and then utilized during an initial consultation. patients complete forms before and after the visit indicating their level of decisional conflict, satisfaction, and satisfaction with decision. pre-determined indices of quality of care were also collected by the study team.

Eligibility criteria:
inclusion criteria: * over age of 18 * able to provide informed consent * able to use a web-based interface * histologically proven or clinically apparent diagnosis of non-small cell lung cancer * newly diagnosed, with new primary occurrence of nsclc, or diagnosed with a new recurrence or new progression of existing disease, and not yet treated for the new problem * being seen in consultation at thoracic oncology clinics exclusion criteria: * unable to fill out questionnaires * already treated for the current diagnosis of a new primary occurrence of nsclc, or already treated for the new recurrence or new progression of existing disease
study of tarceva and targretin oral capsules in patients with advanced lung cancer

Conditions: Carcinoma, Non-small-cell Lung

Summary: the purpose of this study is to learn about the effects of two new anticancer drugs, erlotinib (tarceva) and bexarotene (targretin), when treating patients with advanced lung cancer. erlotinib is approved by the food and drug administration (fda) for the treatment of non-small-cell lung cancer (nsclc). bexarotene is approved by the fda for the treatment of cutaneous t-cell lymphoma. this combination of drugs is experimental.

this is a single institution open label phase ii trial. consecutive, eligible patients presenting with the diagnosis of advanced nsclc are to be enrolled in this study. all eligible patients will receive continuous daily oral erlotinib 150 mg (tarceva™) with daily bexarotene oral capsules 400 mg/m2 (targretin®). the two agents will be taken at the same time. we anticipate the maximum accrual of 40 patients to this trial. patients will be evaluated by history, physical examination, and laboratory assessment every 4 weeks. radiographic disease assessments by chest radiograph will be obtained every 4 weeks and computer tomography every 8 weeks or longer if clinically indicated. whole body pet scan will be obtained at 10 days and 8 weeks. all radiographic studies will be sent to medical metrix solutions (mms) for an independent radiographic review of tumor response.

Eligibility criteria:
inclusion criteria: * advanced nsclc * prior chemotherapy or radiotherapy is allowed. exclusion criteria: * hepatic or renal dysfunction

Keywords: tarceva targretin non-small cell lung cancer carcinoma, non-small cell lung cancer nsclc
a study of jnj-26866138 (bortezomib) in untreated multiple myeloma patients who are not candidates for hematopoietic stem cell transplant (hsct)

Conditions: Multiple Myeloma

Summary: the purpose of the study in phase i is to select the recommended dose of bortezomib in combination with melphalan and prednisolone in japanese participants. in phase ii, to assess the effectiveness and safety of the recommended dose of bortezomib (selected in the phase i portion).

this is an open-label (both physician and participant know the intervention), non-randomized (participants are not assigned by chance), multi-center study in untreated multiple myeloma participants who were not candidates for hematopoietic stem cell transplant. this study consists of two parts: phase i and phase ii. in phase i, a total of 18 participants will be enrolled ie, 6 patients per dose level (0.7, 1.0 and 1.3 mg/m2) to determine the recommended dose of bortezomib. in phase ii, additional 83 participants will be enrolled. safety evaluations will include assessment of adverse events, clinical laboratory test, specifically hematological toxicities.

Eligibility criteria:
inclusion criteria: * participants diagnosed with symptomatic or nonsecretory multiple myeloma * participants who have not received chemotherapy and are not hematopoietic stem cell transplantation candidates * participants with a measurable lesion * life expectancy greater than or equal to 3 months exclusion criteria: * previously received treatment for multiple myeloma * greater than or equal to grade 2 peripheral neuropathy or neuropathic pain * myocardial infarction within 6 months prior to enrollment or uncontrolled angina, severe uncontrolled ventricular arrhythmias, or clinically significant conduction system abnormalities * patient is known to be seropositive for the human immunodeficiency virus (hiv), hepatitis b surface antigen-positive or active hepatitis c infection * active prior malignancy diagnosed within the last 5 years * female participant who is pregnant or breast-feeding * participant is enrolled in another clinical research study and/or is receiving an investigational agent

Keywords: multiple myeloma hematopoietic stem cell transplant hsct melphalan prednisolone bortezomib jnj-26866138